These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 29087169)

  • 1. Association between FDA black box warnings and Medicare formulary coverage changes.
    Dhruva SS; Karaca-Mandic P; Shah ND; Shaw DL; Ross JS
    Am J Manag Care; 2017 Sep; 23(9):e310-e315. PubMed ID: 29087169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings.
    Solotke MT; Ross JS; Shah ND; Karaca-Mandic P; Dhruva SS
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1201-1217. PubMed ID: 31663461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
    Shaw DL; Dhruva SS; Ross JS
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coverage of New Drugs in Medicare Part D.
    Naci H; Kyriopoulos I; Feldman WB; Hwang TJ; Kesselheim AS; Chandra A
    Milbank Q; 2022 Jun; 100(2):562-588. PubMed ID: 35502786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placement of selected new FDA-approved drugs in Medicare Part D formularies, 2009-2013.
    Stuart BC; Tom SE; Choi M; Johnson A; Sun K; Qato D; Obi EN; Zacker C; Park Y; Arcona S
    Am J Manag Care; 2018 Jun; 24(6):e175-e182. PubMed ID: 29939507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk management policy and black-box warnings: a qualitative analysis of US FDA proceedings.
    Cook DM; Gurugubelli RK; Bero LA
    Drug Saf; 2009; 32(11):1057-66. PubMed ID: 19810777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timing of new black box warnings and withdrawals for prescription medications.
    Lasser KE; Allen PD; Woolhandler SJ; Himmelstein DU; Wolfe SM; Bor DH
    JAMA; 2002 May; 287(17):2215-20. PubMed ID: 11980521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels.
    Yeh JS; Sarpatwari A; Kesselheim AS
    Drug Saf; 2016 Aug; 39(8):709-14. PubMed ID: 27000800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of a transition to more restrictive drug formulary on therapy discontinuation and medication adherence.
    Shirneshan E; Kyrychenko P; Matlin OS; Avila JP; Brennan TA; Shrank WH
    J Clin Pharm Ther; 2016 Feb; 41(1):64-9. PubMed ID: 26778812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The "black box" warning and allergy drugs.
    Aaronson DW
    J Allergy Clin Immunol; 2006 Jan; 117(1):40-4. PubMed ID: 16387582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulary status of drugs in Ontario after Health Canada has issued a serious safety warning: a cohort study.
    Lexchin J
    Int J Risk Saf Med; 2015; 27(3):135-42. PubMed ID: 26410247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicare Part D formulary coverage since program inception: are beneficiaries choosing wisely?
    Jackson EA; Axelsen KJ
    Am J Manag Care; 2008 Nov; 14(11 Suppl):SP29-35. PubMed ID: 18991478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription drug formularies in managed care: concerns for the elderly population.
    Gross DJ
    Clin Ther; 1998; 20(6):1277-91. PubMed ID: 9916619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of safety warnings on ESA prescribing among dialysis patients using an interrupted time series.
    Thamer M; Zhang Y; Lai D; Kshirsagar O; Cotter D
    BMC Nephrol; 2013 Aug; 14():172. PubMed ID: 23927675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Messages about black-box warnings: a comparative analysis of reports from the FDA and lay media in the US.
    Yong PL; Bigman C; Flynn DN; Mittermaier D; Long JA
    Drug Saf; 2009; 32(12):1147-57. PubMed ID: 19916582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals.
    Frank C; Himmelstein DU; Woolhandler S; Bor DH; Wolfe SM; Heymann O; Zallman L; Lasser KE
    Health Aff (Millwood); 2014 Aug; 33(8):1453-9. PubMed ID: 25092848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New and incremental FDA black box warnings from 2008 to 2015.
    Solotke MT; Dhruva SS; Downing NS; Shah ND; Ross JS
    Expert Opin Drug Saf; 2018 Feb; 17(2):117-123. PubMed ID: 29215916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deciding which drugs get onto the formulary: a value-based approach.
    Seigfried RJ; Corbo T; Saltzberg MT; Reitz J; Bennett DA
    Value Health; 2013; 16(5):901-6. PubMed ID: 23947985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of orphan drug coverage restrictions in Medicare Part D.
    Yehia F; Segal JB; Anderson GF
    Am J Manag Care; 2020 Sep; 26(9):e289-e294. PubMed ID: 32930558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.